Nicotine Withdrawal and Junk Food Intake: A Study

Mar.28.2022
Nicotine Withdrawal and Junk Food Intake: A Study
Nicotine withdrawal symptoms vary and peak after 1-3 days, but psychological effects can persist. Quitting smoking often leads to increased junk food cravings.

According to a report by foreign media on March 27, 2022, it is well known that the symptoms of nicotine withdrawal vary from person to person, with some struggling more than others. However, these symptoms generally peak in the first 1-3 days of quitting smoking and gradually decrease over the course of 3-4 weeks. After this time, nicotine should be completely eliminated from one's system, but psychological effects often continue to persist.

 

When nicotine enters the bloodstream, it activates the reward and pleasure pathways in the brain by increasing the levels of dopamine, a neurotransmitter responsible for feelings of well-being. It is known to affect areas in the brain that regulate breathing, memory (enhancing it), appetite, and heart rate. The brain quickly becomes addicted to this stimulating effect.

 

Additionally, smokers often turn to smoking when socializing with friends, feeling bored, or in need of a pick-me-up. Over time, this can cause the brain to associate smoking with pleasure, making it difficult to overcome psychological withdrawal symptoms even after overcoming physical nicotine withdrawal symptoms.

 

The physical symptoms of nicotine withdrawal.

 

When the nicotine receptors in the brain are suddenly deprived of nicotine, the release of dopamine decreases. This can naturally lead to an uncomfortable sensation and a strong craving for smoking, as the body has become accustomed to the need for dopamine release. The craving for nicotine can last for 5 to 30 minutes, can be very uncomfortable, and will only subside over time or with the use of nicotine replacement therapy (NRT).

 

A recent study titled "Quitting Smoking Increases Junk Food Intake: The Role of Endogenous Opioid System" has been published in the Journal of Drug and Alcohol Dependence. The lead author of the study, Dr. Mustafa al'Absi, is a licensed psychologist and professor in the Department of Family Medicine and Bio-behavioral Health at the University of Minnesota Medical School. His team researched the brain functions responsible for addiction and appetite regulation, specifically examining the potential preference for junk food during nicotine withdrawal.

 

Researchers studied a group of smoking and non-smoking participants between the ages of 18 and 75. They were randomly assigned to quit using nicotine products for 24 hours and given either a placebo or 50mg of naltrexone. At the end of each session, participants were given snacks with varying calorie levels, salt, sugar, and fat content.

 

As expected, a research group has found that participants who quit smoking tend to choose foods that are high in calories, salt, fat, and sugar. The study observed the involvement of receptors in the brain's opioid system in this behavior. The study shows that food choices and consumption are influenced by smoking status (abstinence > occasional smokers or non-smokers; p < .05), opioid antagonists (naltrexone < placebo; p < .05), and gender (males > females; p < .05). These effects were confirmed for high-sugar and high-fat foods, but no differences were found in low-sugar and low-fat foods.

 

Researchers have concluded that the use of food, particularly high-calorie food, is often employed as a coping mechanism for the negative effects and discomfort experienced by individuals during the process of quitting smoking.

 

(Source: Vaping Post)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Philip Morris International has published its first report aligned with the Taskforce on Nature-related Financial Disclosures, bringing its electronics supply chain and the use and end-of-life stages of smoke-free devices and consumables into its nature-related assessment. PMI said its smoke-free business accounted for about 42% of total net revenues in the second quarter of 2026. The report says non-circular electronic products, particularly single-use items, can increase consumption of limited natural resources and also details an IQOS repair pilot. A 2040 circularity scenario tests assumptions including a 50% reduction in product waste-related costs, 10% raw-material savings and a 25% substitution rate for refurbished products versus new products.
Sep.23
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13